<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 21 - FOOD AND DRUGS</title></head><body>
<span style="font-weight:bold;font-size:12pt;">21 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 2003 Edition</span><br/>
<span style="font-size:10pt">Title 21 - FOOD AND DRUGS</span><br/>
<span style="font-size:10pt">CHAPTER 9 - FEDERAL FOOD, DRUG, AND COSMETIC ACT</span><br/>
<span style="font-size:10pt">Front Matter</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- field-start:notes -->
<!-- field-start:miscellaneous-note -->
<h4 class="note-head">Part A&mdash;Drugs and Devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">351.</div><div class="two-column-analysis-style-content-right">Adulterated drugs and devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Poisonous, insanitary, etc., ingredients; adequate controls in manufacture.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Strength, quality, or purity differing from official compendium.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Misrepresentation of strength, etc., where drug is unrecognized in compendium.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Mixture with or substitution of another substance.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Devices not in conformity with performance standards.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Certain class III devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Banned devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Manufacture, packing, storage, or installation of device not in conformity with applicable requirements or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Failure to comply with requirements under which device was exempted for investigational use.</div></div>
<div><div class="two-column-analysis-style-content-left">352.</div><div class="two-column-analysis-style-content-right">Misbranded drugs and devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">False or misleading label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Package form; contents of label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Prominence of information on label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Designation of drugs or devices by established names.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Directions for use and warnings on label.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Representations as recognized drug; packing and labeling; inconsistent requirements for designation of drug.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Deteriorative drugs; packing and labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Drug; misleading container; imitation; offer for sale under another name.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Health-endangering when used as prescribed.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k),</div><div class="two-column-analysis-style-content-subitem-right" id="wide">(<em>l</em>)&nbsp;Repealed.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Color additives; packing and labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Prescription drug advertisements: established name; quantitative formula; side effects, contraindications, and effectiveness; prior approval; false advertising; labeling; construction of the Convention on Psychotropic Substances.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>o</em>)</div><div class="two-column-analysis-style-content-subitem-right">Drugs or devices from nonregistered establishments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(p)</div><div class="two-column-analysis-style-content-subitem-right">Packaging or labeling of drugs in violation of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(q)</div><div class="two-column-analysis-style-content-subitem-right">Restricted devices using false or misleading advertising or used in violation of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(r)</div><div class="two-column-analysis-style-content-subitem-right">Restricted devices not carrying requisite accompanying statements in advertisements and other descriptive printed matter.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(s)</div><div class="two-column-analysis-style-content-subitem-right">Devices subject to performance standards not bearing requisite labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(t)</div><div class="two-column-analysis-style-content-subitem-right">Devices for which there has been a failure or refusal to give required notification or to furnish required material or information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(u)</div><div class="two-column-analysis-style-content-subitem-right">Identification of manufacturer.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(v)</div><div class="two-column-analysis-style-content-subitem-right">Reprocessed single-use devices.</div></div>
<div><div class="two-column-analysis-style-content-left">353.</div><div class="two-column-analysis-style-content-right">Exemptions and consideration for certain drugs, devices, and biological products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Regulations for goods to be processed, labeled, or repacked elsewhere.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Prescription by physician; exemption from labeling and prescription requirements; misbranded drugs; compliance with narcotic and marihuana laws.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Sales restrictions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Distribution of drug samples.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Wholesale distributors; guidelines for licensing; definitions.<!-- PDFPage:28 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Veterinary prescription drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Regulation of combination products.</div></div>
<div><div class="two-column-analysis-style-content-left">353a.</div><div class="two-column-analysis-style-content-right">Pharmacy compounding.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Compounded drug.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Advertising and promotion.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">&ldquo;Compounding&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-left">354.</div><div class="two-column-analysis-style-content-right">Veterinary feed directive drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Lawful veterinary feed directive requirement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Labeling and advertising.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Nonprescription status.</div></div>
<div><div class="two-column-analysis-style-content-left">355.</div><div class="two-column-analysis-style-content-right">New drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Necessity of effective approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Filing application; contents.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Grounds for refusing application; approval of application; &ldquo;substantial evidence&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to public health.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Revocation of order refusing, withdrawing or suspending approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Service of orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Appeal from order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Exemptions of drugs for research; discretionary and mandatory conditions; direct reports to Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Abbreviated new drug applications.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Records and reports; required information; regulations and orders; access to records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Public disclosure of safety and effectiveness data.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">&ldquo;Patent&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Scientific advisory panels.</div></div>
<div><div class="two-column-analysis-style-content-left">355a.</div><div class="two-column-analysis-style-content-right">Pediatric studies of drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Market exclusivity for new drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Market exclusivity for already-marketed drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Conduct of pediatric studies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Delay of effective date for certain application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Notice of determinations on studies requirement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Limitations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Relationship to pediatric research requirements.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Labeling supplements.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Dissemination of pediatric information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Clarification of interaction of market exclusivity under this section and market exclusivity awarded to an applicant for approval of a drug under section 355(j) of this title.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Prompt approval of drugs under section 355(j) of this title when pediatric information is added to labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Report.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Sunset.</div></div>
<div><div class="two-column-analysis-style-content-left">355b.</div><div class="two-column-analysis-style-content-right">Adverse-event reporting.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Toll-free number in labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Drugs with pediatric market exclusivity.</div></div>
<div><div class="two-column-analysis-style-content-left">355c.</div><div class="two-column-analysis-style-content-right">Research into pediatric uses for drugs and biological products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">New drugs and biological products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Marketed drugs and biological products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Meaningful therapeutic benefit.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Submission of assessments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Meetings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Scope of authority.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Orphan drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Integration with other pediatric studies.</div></div>
<div><div class="two-column-analysis-style-content-left">356.</div><div class="two-column-analysis-style-content-right">Fast track products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Designation of drug as fast track product.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Approval of application for fast track product.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Review of incomplete applications for approval of fast track product.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Awareness efforts.</div></div>
<div><div class="two-column-analysis-style-content-left">356&ndash;1.</div><div class="two-column-analysis-style-content-right">Accelerated approval of priority countermeasures.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Use of animal trials.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Priority review of drugs and biological products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">356a.</div><div class="two-column-analysis-style-content-right">Manufacturing changes.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Validation of effects of changes.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Major manufacturing changes.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Other manufacturing changes.</div></div>
<div><div class="two-column-analysis-style-content-left">356b.</div><div class="two-column-analysis-style-content-right">Reports of postmarketing studies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Submission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Consideration of information as public information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Status of studies and reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Disclosure.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Notification.</div></div>
<div><div class="two-column-analysis-style-content-left">356c.</div><div class="two-column-analysis-style-content-right">Discontinuance of life saving product.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Reduction in notification period.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Distribution.</div></div>
<div><div class="two-column-analysis-style-content-left">357.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">358.</div><div class="two-column-analysis-style-content-right">Authority to designate official names.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Necessity or desirability; use in official compendiums; infringement of trademarks.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Review of names in official compendiums.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Determinations of complexity, usefulness, multiplicity, or lack of name; designation by Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Revised official names; compilation, publication, and public distribution of listings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Request by compiler of official compendium for designation of name.</div></div>
<div><div class="two-column-analysis-style-content-left">359.</div><div class="two-column-analysis-style-content-right">Nonapplicability of subchapter to cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">360.</div><div class="two-column-analysis-style-content-right">Registration of producers of drugs or devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Annual registration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">New producers.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Additional establishments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Registration number; uniform system for identification of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Availability of registrations for inspection.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Exclusions from application of section.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Inspection of premises.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Registration of foreign establishments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Filing of lists of drugs and devices manufactured, prepared, propagated and compounded by registrants; statements; accompanying disclosures.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Report preceding introduction of devices into interstate commerce.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Exemption from reporting requirements.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">List of exempt class II devices; determination by Secretary; publication in Federal Register.<!-- PDFPage:29 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Review of report; time for determination by Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>o</em>)</div><div class="two-column-analysis-style-content-subitem-right">Reprocessed single-use devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(p)</div><div class="two-column-analysis-style-content-subitem-right">Electronic registration.</div></div>
<div><div class="two-column-analysis-style-content-left">360a.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">360b.</div><div class="two-column-analysis-style-content-right">New animal drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Unsafe new animal drugs and animal feed containing such drugs; conditions of safety; exemption of drugs for research; import tolerances.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Filing application for uses of new animal drug; contents; patent information; abbreviated application; presubmission conference.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Period for submission and approval of application; period for notice and expedition of hearing; period for issuance of order; abbreviated applications; withdrawal periods; effective date of approval; relationship to other applications; withdrawal or suspension of approval; bioequivalence; filing of additional patent information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Grounds for refusing application; approval of application; factors; &ldquo;substantial evidence&rdquo; defined; combination drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to health of man or animals.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Revocation of order refusing, withdrawing or suspending approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Service of orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Appeal from order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Publication in Federal Register; effective date and revocation or suspension of regulation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Exemption of drugs for research; discretionary and mandatory conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Food containing new animal drug considered unadulterated while approval of application for such drug is effective.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Records and reports; required information; regulations and orders; examination of data; access to records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Feed mill licenses.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Abbreviated applications for new animal drugs; contents, filing, etc.; lists of approved drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>o</em>)</div><div class="two-column-analysis-style-content-subitem-right">&ldquo;Patent&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(p)</div><div class="two-column-analysis-style-content-subitem-right">Safety and effectiveness data.</div></div>
<div><div class="two-column-analysis-style-content-left">360c.</div><div class="two-column-analysis-style-content-right">Classification of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Classes of devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Classification panels.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Classification panel organization and operation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Panel recommendation; publication; priorities.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Classification changes.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Initial classification and reclassification of certain devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Substantial equivalence.</div></div>
<div><div class="two-column-analysis-style-content-left">360d.</div><div class="two-column-analysis-style-content-right">Performance standards.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Reasonable assurance of safe and effective performance; periodic evaluation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Establishment of a standard.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Recognition of standard.</div></div>
<div><div class="two-column-analysis-style-content-left">360e.</div><div class="two-column-analysis-style-content-right">Premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General requirement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulation to require premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Application for premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Action on application for premarket approval.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Withdrawal and temporary suspension of approval of application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Product development protocol.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Service of orders.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Revision.</div></div>
<div><div class="two-column-analysis-style-content-left">360f.</div><div class="two-column-analysis-style-content-right">Banned devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Special effective date.</div></div>
<div><div class="two-column-analysis-style-content-left">360g.</div><div class="two-column-analysis-style-content-right">Judicial review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Petition; record.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Additional data, views, and arguments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Standard for review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Finality of judgments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Remedies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Statement of reasons.</div></div>
<div><div class="two-column-analysis-style-content-left">360h.</div><div class="two-column-analysis-style-content-right">Notification and other remedies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Notification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Repair, replacement, or refund.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Reimbursement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Effect on other liability.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Recall authority.</div></div>
<div><div class="two-column-analysis-style-content-left">360i.</div><div class="two-column-analysis-style-content-right">Records and reports on devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">User reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Persons exempt.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Device tracking.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Reports of removals and corrections.</div></div>
<div><div class="two-column-analysis-style-content-left">360j.</div><div class="two-column-analysis-style-content-right">General provisions respecting control of devices intended for human use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Custom devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Trade secrets.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Notices and findings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Restricted devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Good manufacturing practice requirements.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Exemption for devices for investigational use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Release of information respecting safety and effectiveness.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Proceedings of advisory panels and committees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Traceability.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Research and development.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Transitional provisions for devices considered as new drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Humanitarian device exemption.</div></div>
<div><div class="two-column-analysis-style-content-left">360k.</div><div class="two-column-analysis-style-content-right">State and local requirements respecting devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">General rule.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Exempt requirements.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>l.</em></div><div class="two-column-analysis-style-content-right">Postmarket surveillance.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Surveillance approval.</div></div>
<div><div class="two-column-analysis-style-content-left">360m.</div><div class="two-column-analysis-style-content-right">Accredited persons.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Accreditation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Duration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Report.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part B&mdash;Drugs for Rare Diseases or Conditions</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360aa.</div><div class="two-column-analysis-style-content-right">Recommendations for investigations of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Request by sponsor; response by Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-left">360bb.</div><div class="two-column-analysis-style-content-right">Designation of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Request by sponsor; preconditions; &ldquo;rare disease or condition&rdquo; defined.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Notification of discontinuance of drug or application as condition.<!-- PDFPage:30 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Notice to public.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-left">360cc.</div><div class="two-column-analysis-style-content-right">Protection for drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Exclusive approval, certification, or license.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Exceptions.</div></div>
<div><div class="two-column-analysis-style-content-left">360dd.</div><div class="two-column-analysis-style-content-right">Open protocols for investigations of drugs for rare diseases or conditions.</div></div>
<div><div class="two-column-analysis-style-content-left">360ee.</div><div class="two-column-analysis-style-content-right">Grants and contracts for development of drugs for rare diseases and conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority of Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part C&mdash;Electronic Product Radiation Control</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360hh.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">360ii.</div><div class="two-column-analysis-style-content-right">Program of control.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Establishment.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Powers of Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Record keeping.</div></div>
<div><div class="two-column-analysis-style-content-left">360jj.</div><div class="two-column-analysis-style-content-right">Studies by the Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Report to Congress.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Participation of other Federal agencies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Organization of studies and participation.</div></div>
<div><div class="two-column-analysis-style-content-left">360kk.</div><div class="two-column-analysis-style-content-right">Performance standards for electronic products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Promulgation of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Administrative procedure.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Publication in Federal Register.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Judicial review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Availability of record.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Technical Electronic Product Radiation Safety Standards Committee.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Review and evaluation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Product certification.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>ll.</em></div><div class="two-column-analysis-style-content-right">Notification of defects in and repair or replacement of electronic products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Notification; exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Method of notification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Requisite elements of notification.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Copies to Secretary of communications by manufacturers to dealers or distributors regarding defects.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Notice from Secretary to manufacturer of defects or failure to comply with standards.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Correction of defects.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Effective date.</div></div>
<div><div class="two-column-analysis-style-content-left">360mm.</div><div class="two-column-analysis-style-content-right">Imports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Refusal of admission to noncomplying electronic products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Bond.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Liability of owner or consignee for expenses connected with refusal of admission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Designation of agent for purposes of service.</div></div>
<div><div class="two-column-analysis-style-content-left">360nn.</div><div class="two-column-analysis-style-content-right">Inspection, records, and reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Inspection of premises.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Record keeping.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Disclosure of technical data.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Public nature of reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Trade secrets.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Information required to identify and locate first purchasers of electronic products.</div></div>
<div><div class="two-column-analysis-style-content-left">360<em>oo.</em></div><div class="two-column-analysis-style-content-right">Prohibited acts.</div></div>
<div><div class="two-column-analysis-style-content-left">360pp.</div><div class="two-column-analysis-style-content-right">Enforcement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Jurisdiction of courts.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Penalties.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Venue; process.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Warnings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Compliance with regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Additional remedies.</div></div>
<div><div class="two-column-analysis-style-content-left">360qq.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
<div><div class="two-column-analysis-style-content-left">360rr.</div><div class="two-column-analysis-style-content-right">Federal-State cooperation.</div></div>
<div><div class="two-column-analysis-style-content-left">360ss.</div><div class="two-column-analysis-style-content-right">State standards.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part D&mdash;Dissemination of Treatment Information</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360aaa.</div><div class="two-column-analysis-style-content-right">Requirements for dissemination of treatment information on drugs or devices.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Specific requirements.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Additional information.</div></div>
<div><div class="two-column-analysis-style-content-left">360aaa&ndash;1.</div><div class="two-column-analysis-style-content-right">Information authorized to be disseminated.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authorized information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Reference publication.</div></div>
<div><div class="two-column-analysis-style-content-left">360aaa&ndash;2.</div><div class="two-column-analysis-style-content-right">Establishment of list of articles and publications disseminated and list of providers that received articles and reference publications.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Records.</div></div>
<div><div class="two-column-analysis-style-content-left">360aaa&ndash;3.</div><div class="two-column-analysis-style-content-right">Requirement regarding submission of supplemental application for new use; exemption from requirement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Certification on supplemental application; condition in case of completed studies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Certification on supplemental application; condition in caseof planned studies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Exemption from requirement of supplemental application.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Requirements regarding applications.</div></div>
<div><div class="two-column-analysis-style-content-left">360aaa&ndash;4.</div><div class="two-column-analysis-style-content-right">Corrective actions; cessation of dissemination.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Postdissemination data regarding safety and effectiveness.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Cessation of dissemination.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Corrective actions by manufacturers.</div></div>
<div><div class="two-column-analysis-style-content-left">360aaa&ndash;5.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">360aaa&ndash;6.</div><div class="two-column-analysis-style-content-right">Rules of construction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Unsolicited request.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Dissemination of information on drugs or devices not evidence of intended use.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Patent protection.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Authorization for dissemination of articles and fees for reprints of articles.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part E&mdash;General Provisions Relating to Drugs and Devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">360bbb.</div><div class="two-column-analysis-style-content-right">Expanded access to unapproved therapies and diagnostics.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Emergency situations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Individual patient access to investigational products intended for serious diseases.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Treatment investigational new drug applications and treatment investigational device exemptions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Termination.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;1.</div><div class="two-column-analysis-style-content-right">Dispute resolution.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;2.</div><div class="two-column-analysis-style-content-right">Classification of products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Request.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Statement.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Inaction of Secretary.</div></div>
<div><div class="two-column-analysis-style-content-left">360bbb&ndash;3.</div><div class="two-column-analysis-style-content-right">Authorization for medical products for use in emergencies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Declaration of emergency.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Criteria for issuance of authorization.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Scope of authorization.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Conditions of authorization.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Duration of authorization.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Revocation of authorization.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Publication; confidential information.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Actions committed to agency discretion.<!-- PDFPage:31 --></div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Rules of construction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Relation to other provisions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Option to carry out authorized activities.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VI&mdash;COSMETICS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">361.</div><div class="two-column-analysis-style-content-right">Adulterated cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">362.</div><div class="two-column-analysis-style-content-right">Misbranded cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-left">363.</div><div class="two-column-analysis-style-content-right">Regulations making exemptions.</div></div>
<div><div class="two-column-analysis-style-content-left">364.</div><div class="two-column-analysis-style-content-right" id="wide">Repealed.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VII&mdash;GENERAL AUTHORITY</h4>
<h4 class="note-head">Part A&mdash;General Administrative Provisions</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">371.</div><div class="two-column-analysis-style-content-right">Regulations and hearings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority to promulgate regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulations for imports and exports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Conduct of hearings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Effectiveness of definitions and standards of identity.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Procedure for establishment.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Review of order.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Copies of records of hearings.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Guidance documents.</div></div>
<div><div class="two-column-analysis-style-content-left">372.</div><div class="two-column-analysis-style-content-right">Examinations and investigations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority to conduct.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Availability to owner of part of analysis samples.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Records of other departments and agencies.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Information on patents for drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Powers of enforcement personnel.</div></div>
<div><div class="two-column-analysis-style-content-left">372a.</div><div class="two-column-analysis-style-content-right">Transferred.</div></div>
<div><div class="two-column-analysis-style-content-left">373.</div><div class="two-column-analysis-style-content-right">Records of interstate shipment.</div></div>
<div><div class="two-column-analysis-style-content-left">374.</div><div class="two-column-analysis-style-content-right">Inspection.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Right of agents to enter; scope of inspection; notice; promptness; exclusions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Written report to owner; copy to Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Receipt for samples taken.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Analysis of samples furnished owner.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Accessibility of records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Recordkeeping.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Inspections by accredited persons.</div></div>
<div><div class="two-column-analysis-style-content-left">375.</div><div class="two-column-analysis-style-content-right">Publicity.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Reports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Information regarding certain goods.</div></div>
<div><div class="two-column-analysis-style-content-left">376.</div><div class="two-column-analysis-style-content-right">Examination of sea food on request of packer; marking food with results; fees; penalties.</div></div>
<div><div class="two-column-analysis-style-content-left">377.</div><div class="two-column-analysis-style-content-right">Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests.</div></div>
<div><div class="two-column-analysis-style-content-left">378.</div><div class="two-column-analysis-style-content-right">Advertising of foods.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Determination of misbranding; notification of Federal Trade Commission by Secretary; contents.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Action by Federal Trade Commission precluding action by Secretary; exception.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Secretary's determination of imminent hazard to health as suspending applicability of provisions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Coordination of action by Secretary with Federal Trade Commission.</div></div>
<div><div class="two-column-analysis-style-content-left">379.</div><div class="two-column-analysis-style-content-right">Confidential information.</div></div>
<div><div class="two-column-analysis-style-content-left">379a.</div><div class="two-column-analysis-style-content-right">Presumption of existence of jurisdiction.</div></div>
<div><div class="two-column-analysis-style-content-left">379b.</div><div class="two-column-analysis-style-content-right">Consolidated administrative and laboratory facility.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Authority.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Awarding of contract.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Donations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
<div><div class="two-column-analysis-style-content-left">379c.</div><div class="two-column-analysis-style-content-right">Transferred.</div></div>
<div><div class="two-column-analysis-style-content-left">379d.</div><div class="two-column-analysis-style-content-right">Automation of Food and Drug Administration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part B&mdash;Colors</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379e.</div><div class="two-column-analysis-style-content-right">Listing and certification of color additives for foods, drugs, devices, and cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Unsafe color additives.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Listing of colors; regulations; issuance, amendment or repeal; referral to advisory committee; report and recommendations; appointment and compensation of advisory committee.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Certification of colors.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Procedure for issuance, amendment, or repeal of regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Exemptions.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part C&mdash;Fees</h4>
I74subpart 1&mdash;freedom of information fees<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379f.</div><div class="two-column-analysis-style-content-right">Recovery and retention of fees for freedom of information requests.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Use of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Waiver of fees.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 2&mdash;fees relating to drugs</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379g.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">379h.</div><div class="two-column-analysis-style-content-right">Authority to assess and use drug fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Types of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Fee revenue amounts.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Adjustments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Fee waiver or reduction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Effect of failure to pay fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Limitations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Crediting and availability of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Collection of unpaid fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Written requests for waivers, reductions, and refunds.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Construction.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 3&mdash;fees relating to devices</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379i.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">379j.</div><div class="two-column-analysis-style-content-right">Authority to assess and use device fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Types of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Fee revenue amounts.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Adjustments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Small businesses; fee waiver and fee reduction regarding premarket approval fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Small businesses; fee reduction regarding premarket notification submissions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Effect of failure to pay fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Conditions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Crediting and availability of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Collection of unpaid fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Written requests for refunds.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Construction.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">subpart 4&mdash;fees relating to animal drugs</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379j&ndash;11.</div><div class="two-column-analysis-style-content-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-left">379j&ndash;12.</div><div class="two-column-analysis-style-content-right">Authority to assess and use animal drug fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Types of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Fee amounts.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Adjustments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Fee waiver or reduction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Effect of failure to pay fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Assessment of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Crediting and availability of fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Collection of unpaid fees.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Written requests for waivers, reductions, and refunds.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Construction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Abbreviated new animal drug applications.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part D&mdash;Information and Education</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379k.</div><div class="two-column-analysis-style-content-right">Information system.</div></div>
<div><div class="two-column-analysis-style-content-left">379<em>l</em>.</div><div class="two-column-analysis-style-content-right">Education.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Intramural fellowships and other training programs.<!-- PDFPage:32 --></div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part E&mdash;Environmental Impact Review</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379<em>o</em>.</div><div class="two-column-analysis-style-content-right">Environmental impact.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part F&mdash;National Uniformity for Nonprescription Drugs and Preemption for Labeling or Packaging of Cosmetics</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379r.</div><div class="two-column-analysis-style-content-right">National uniformity for nonprescription drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Scope.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Exceptions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">No effort on product liability law.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">State enforcement authority.</div></div>
<div><div class="two-column-analysis-style-content-left">379s.</div><div class="two-column-analysis-style-content-right">Preemption for labeling or packaging of cosmetics.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Scope.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">No effect on product liability law.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">State initiative.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="note-head">Part G&mdash;Safety Reports</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">379v.</div><div class="two-column-analysis-style-content-right">Safety report disclaimers.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER VIII&mdash;IMPORTS AND EXPORTS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">381.</div><div class="two-column-analysis-style-content-right">Imports and exports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Imports; list of registered foreign establishments; samples from unregistered foreign establishments; examination and refusal of admission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Disposition of refused articles.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Charges concerning refused articles.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Reimportation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Exports.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Labeling of exported drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Warning notice of importation in violation of chapter.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Protection against adulteration of food.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Testing for rapid detection of adulteration of food.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Temporary holds at ports of entry.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Importation by debarred persons.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Failure to register.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Prior notice of imported food shipments.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(n)</div><div class="two-column-analysis-style-content-subitem-right">Labeling of food refused admission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>o</em>)</div><div class="two-column-analysis-style-content-subitem-right">Registration statement.</div></div>
<div><div class="two-column-analysis-style-content-left">382.</div><div class="two-column-analysis-style-content-right">Exports of certain unapproved products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Drugs or devices intended for human or animal use which require approval or licensing.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">List of eligible countries for export; criteria for addition to list; direct export; petition for exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Investigational use exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Anticipation of market authorization.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Diagnosis, prevention, or treatment of tropical disease.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Prohibition of export of drug or device.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Notification of Secretary.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">References to Secretary and term &ldquo;drug&rdquo;.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Exportation.</div></div>
<div><div class="two-column-analysis-style-content-left">383.</div><div class="two-column-analysis-style-content-right">Office of International Relations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Establishment.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Agreements with foreign countries.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Harmonizing regulatory requirements.</div></div>
<div><div class="two-column-analysis-style-content-left">384.</div><div class="two-column-analysis-style-content-right">Importation of prescription drugs.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Definitions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Regulations.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Limitation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Information and records.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Testing.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Registration of foreign sellers.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Suspension of importation.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(h)</div><div class="two-column-analysis-style-content-subitem-right">Approved labeling.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(i)</div><div class="two-column-analysis-style-content-subitem-right">Charitable contributions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(j)</div><div class="two-column-analysis-style-content-subitem-right">Waiver authority for importation by individuals.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(k)</div><div class="two-column-analysis-style-content-subitem-right">Construction.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(<em>l</em>)</div><div class="two-column-analysis-style-content-subitem-right">Effectiveness of section.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(m)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<h4 class="analysis-subhead">SUBCHAPTER IX&mdash;MISCELLANEOUS</h4>
<div class="analysis">
<div><div class="two-column-analysis-style-content-left">391.</div><div class="two-column-analysis-style-content-right">Separability clause.</div></div>
<div><div class="two-column-analysis-style-content-left">392.</div><div class="two-column-analysis-style-content-right">Exemption of meats and meat food products.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Law determinative of exemption.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Laws unaffected.</div></div>
<div><div class="two-column-analysis-style-content-left">393.</div><div class="two-column-analysis-style-content-right">Food and Drug Administration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Mission.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Interagency collaboration.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(d)</div><div class="two-column-analysis-style-content-subitem-right">Commissioner.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(e)</div><div class="two-column-analysis-style-content-subitem-right">Technical and scientific review groups.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(f)</div><div class="two-column-analysis-style-content-subitem-right">Agency plan for statutory compliance.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(g)</div><div class="two-column-analysis-style-content-subitem-right">Annual report.</div></div>
<div><div class="two-column-analysis-style-content-left">393a.</div><div class="two-column-analysis-style-content-right">Office of Pediatric Therapeutics.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">Establishment.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Duties.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Staff.</div></div>
<div><div class="two-column-analysis-style-content-left">394.</div><div class="two-column-analysis-style-content-right">Scientific review groups.</div></div>
<div><div class="two-column-analysis-style-content-left">395.</div><div class="two-column-analysis-style-content-right">Loan repayment program.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Applicability of certain provisions.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
<div><div class="two-column-analysis-style-content-left">396.</div><div class="two-column-analysis-style-content-right">Practice of medicine.</div></div>
<div><div class="two-column-analysis-style-content-left">397.</div><div class="two-column-analysis-style-content-right">Contracts for expert review.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Review of expert review.</div></div>
<div><div class="two-column-analysis-style-content-left">398.</div><div class="two-column-analysis-style-content-right">Notices to States regarding imported food.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Rule of construction.</div></div>
<div><div class="two-column-analysis-style-content-left">399.</div><div class="two-column-analysis-style-content-right">Grants to States for inspections.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(a)</div><div class="two-column-analysis-style-content-subitem-right">In general.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(b)</div><div class="two-column-analysis-style-content-subitem-right">Notices regarding adulterated imported food.</div></div>
<div><div class="two-column-analysis-style-content-subitem-left">(c)</div><div class="two-column-analysis-style-content-subitem-right">Authorization of appropriations.</div></div>
</div>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<!-- field-end:miscellaneous-note -->
<!-- field-end:notes -->
<!-- field-start:secref -->
<h4 class="note-head">Chapter Referred to in Other Sections</h4>
<!-- field-end:secref -->
<!-- field-start:sectionreferredto -->
<p class="note-body">This chapter is referred to in sections 321d, 355b, 453, 457, 466, 467, 467f, 601, 607, 620, 679, 802, 811, 823, 829, 830, 902, 1033, 1049, 1052, 1401, 1402, 1403, 1601 of this title; title 7 sections 136a&ndash;1, 136v, 138i, 1431c, 5341, 6519, 7653, 8401; title 15 sections 70j, 1261, 1263, 1277, 1459, 1460, 2057a, 2057b, 2079; title 18 sections 42, 983; title 19 section 2578a; title 26 sections 170, 4817; title 35 sections 155, 156, 271, 287; title 42 sections 238q, 262, 262a, 284m, 299b&ndash;7, 300aa&ndash;22, 300aa&ndash;23, 1395w&ndash;3, 1395w&ndash;3b, 1396r&ndash;8, 1786, 3512, 7671.</p>
<!-- field-end:sectionreferredto -->


</body></html>